Patients with hematologic malignancies are well known to have prolonged COVID-19 pneumonia. The cause has been reported to be B cell depletion after administration of anti-CD20 antibodies. Here, we report a case of COVID-19 pneumonia due to prolonged B-cell depletion after anti-CD20 antibody therapy for malignant lymphoma two years before. Sotrovimab, a neutralizing antibody that was designed to prevent the progression of COVID-19, was successful in preventing the progression to severe disease in this B-cell-depleted patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404336 | PMC |
| http://dx.doi.org/10.7759/cureus.41486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protracted COVID-19 pneumonia in B cell depleted patients.
Rheumatology (Oxford)
December 2024
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients.
Rheum Dis Clin North Am
February 2025
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Biomedicine, Aarhus University, Aarhus, Denmark. Electronic address:
This article provides a comprehensive review of the impact of B-cell-directed therapy on severe acute respiratory syndrome coronavirus 2 vaccine immunity, focusing on its implications in autoimmune inflammatory rheumatic diseases (AIIRD). Rituximab (RTX) is the primary B-cell-depleting drug that has been studied in AIIRD and is the focus of this review. We review the pivotal role of B cells in vaccine response and propose strategies to manage and predict vaccine responses in B-cell-depleted individuals.
View Article and Find Full Text PDFImpact of Continuous Ofatumumab Exposure During Pregnancy in Multiple Sclerosis.
Neurol Clin Pract
February 2025
Department of Neurology (SH, TLC, FO, TM), Christian-Doppler Clinic, University Hospital of Salzburg; Division of Neonatology (EH), Department of Pediatrics and Adolescent Medicine, Paracelsus Medical University, Salzburg, Austria; and St. Josef-Hospital/ Ruhr-University Bochum (KH), Germany.
Objectives: Anti-CD20 therapies are highly effective treatment options for patients with multiple sclerosis (MS), an inflammatory disorder of the CNS commonly affecting women of childbearing age. Anti-CD20 therapies are however unlicensed for use in pregnancy. Belonging to the IgG1 family, anti-CD20 monoclonal antibodies are likely to cross the placenta, especially after the 20th week of gestation.
View Article and Find Full Text PDFCharacterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.
PLoS Pathog
October 2024
Institute of Virology Muenster, University of Muenster, Muenster, Germany.
Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the humoral immune response causing intra-host evolution in a B-cell depleted, haemato-oncologic patient experiencing clinically severe, prolonged SARS-CoV-2 infection with a virus of lineage B.1.
View Article and Find Full Text PDFMeningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis.
Eur J Clin Microbiol Infect Dis
November 2024
Institute of Microbiology - Clinical Microbiology, Immunology and Hygiene, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Mycoplasma pneumoniae, a frequent respiratory pathogen, can cause neurological disease manifestations. We here present a case of M. pneumoniae as cause of meningitis and occurrence of an intracranial abscess as a complication of mastoiditis with septic cerebral venous sinus thrombosis in a patient with multiple sclerosis on anti-CD20 therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!